In The News Posted September 5, 2019 Share Posted September 5, 2019 Patients are advised to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan, Sept. 5,... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.